ATE448211T1 - 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie - Google Patents

1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie

Info

Publication number
ATE448211T1
ATE448211T1 AT06726008T AT06726008T ATE448211T1 AT E448211 T1 ATE448211 T1 AT E448211T1 AT 06726008 T AT06726008 T AT 06726008T AT 06726008 T AT06726008 T AT 06726008T AT E448211 T1 ATE448211 T1 AT E448211T1
Authority
AT
Austria
Prior art keywords
production
triazine derivatives
human therapy
therapy
human
Prior art date
Application number
AT06726008T
Other languages
English (en)
Inventor
Elisabeth Dupont-Passelaigue
Isabelle Leroy
Jean-Francois Patoiseau
Didier Junquero
Yves Rival
Andre Delhon
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE448211T1 publication Critical patent/ATE448211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
AT06726008T 2005-03-03 2006-03-02 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie ATE448211T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502152A FR2882750B1 (fr) 2005-03-03 2005-03-03 Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
PCT/FR2006/000469 WO2006092507A1 (fr) 2005-03-03 2006-03-02 Derives de 1 ,2,4-triazines, leur preparation et leur application en therapeutique humaine

Publications (1)

Publication Number Publication Date
ATE448211T1 true ATE448211T1 (de) 2009-11-15

Family

ID=35116027

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06726008T ATE448211T1 (de) 2005-03-03 2006-03-02 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie

Country Status (27)

Country Link
US (1) US7713971B2 (de)
EP (1) EP1856065B1 (de)
JP (1) JP5269420B2 (de)
KR (1) KR20070112230A (de)
CN (1) CN101155790A (de)
AR (1) AR053155A1 (de)
AT (1) ATE448211T1 (de)
AU (1) AU2006219802A1 (de)
BR (1) BRPI0607567A2 (de)
CA (1) CA2599848A1 (de)
CR (1) CR9366A (de)
DE (1) DE602006010337D1 (de)
ES (1) ES2336823T3 (de)
FR (1) FR2882750B1 (de)
IL (1) IL185586A0 (de)
MA (1) MA29343B1 (de)
MX (1) MX2007010787A (de)
MY (1) MY140662A (de)
NI (1) NI200700224A (de)
NO (1) NO20074881L (de)
PL (1) PL1856065T3 (de)
PT (1) PT1856065E (de)
RU (1) RU2007136027A (de)
TN (1) TNSN07335A1 (de)
TW (1) TW200643016A (de)
WO (1) WO2006092507A1 (de)
ZA (1) ZA200707730B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736229C (en) * 2008-09-05 2015-06-09 Acucela Inc. Sulfur-linked compounds for treating opthalmic diseases and disorders
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
JP6814730B2 (ja) * 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
TWI840423B (zh) * 2018-10-12 2024-05-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine

Also Published As

Publication number Publication date
WO2006092507A8 (fr) 2007-11-01
ZA200707730B (en) 2008-05-28
BRPI0607567A2 (pt) 2011-10-18
CR9366A (es) 2008-02-12
CA2599848A1 (fr) 2006-09-08
WO2006092507A1 (fr) 2006-09-08
NI200700224A (es) 2008-03-27
US20080167313A1 (en) 2008-07-10
KR20070112230A (ko) 2007-11-22
MA29343B1 (fr) 2008-03-03
ES2336823T3 (es) 2010-04-16
PL1856065T3 (pl) 2010-04-30
AU2006219802A1 (en) 2006-09-08
PT1856065E (pt) 2010-02-10
EP1856065B1 (de) 2009-11-11
CN101155790A (zh) 2008-04-02
US7713971B2 (en) 2010-05-11
JP5269420B2 (ja) 2013-08-21
DE602006010337D1 (de) 2009-12-24
TNSN07335A1 (fr) 2008-12-31
TW200643016A (en) 2006-12-16
RU2007136027A (ru) 2009-04-10
MX2007010787A (es) 2007-09-25
IL185586A0 (en) 2008-01-06
FR2882750B1 (fr) 2007-05-11
MY140662A (en) 2010-01-15
FR2882750A1 (fr) 2006-09-08
JP2008531662A (ja) 2008-08-14
NO20074881L (no) 2007-11-27
EP1856065A1 (de) 2007-11-21
AR053155A1 (es) 2007-04-25

Similar Documents

Publication Publication Date Title
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
ATE469131T1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
ATE409184T1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE519727T1 (de) 4-chlor-4-alkoxy-1,1,1-trifluor-2-butanone, deren herstellung und deren verwendung bei der herstellung von 4-alkoxy-1,1,1-trifluor-3-buten-2-onen
ATE423119T1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
ATE336491T1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE548349T1 (de) In stellung 3 disubstituierte indol-2-on- pyridinderivate, ihre herstellung sowie ihre therapeutische anwendung
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
ATE448211T1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
DE602006008971D1 (de) N-ä(4,5-diphenylpyrimidin-2-yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
ATE411295T1 (de) 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties